EDITOR: | February 21st, 2017

BlueOcean in position to tap three huge markets with antioxidant

| February 21, 2017 | No Comments
image_pdfimage_print

BlueOcean NutraSciences Inc. (TSXV: BOC) announced that it will restart its dormant algae gas infusion subsidiary targeting commercial Omega-3 and astaxanthin based algae companies utilizing minimal capital or resources.

The core technology for gas infusion technology, which has been developed and patented by Canzone Limited, offers a significant reduction in capital and operating costs for the production of algae rich in astaxanthin.

Previous results shows that algal growth is accelerated by up to 300% when grown in CO2 gas dissolved and infused water versus baseline traditional micro bubbling of CO2 gas, which is the traditional method for growing algae.

Algae are photosynthetic organisms that use CO2 as carbon source through photosynthesis.

BlueOcean plans to engage existing producers of algae. Their first challenge is to study the algae growth kinetics at the bench scale to understand the variables that affect production. Once satisfied with the production parameters, BlueOcean plans to enter into agreements for the production of algae through gas infusion with existing commercial algae operations on royalty or incremental yield sharing models.

Algae are the primary source of astaxanthin in the sea but industrial production of astaxanthin depends on Haematococcus pluvialis, which can accumulate over 40 g of astaxanthin from one kg of dry biomass.

Astaxanthin is sold as an antioxidant and has been recommended for the treatment of inflammation, Alzheimer’s disease, Parkinson’s disease, “brain attack” (stroke), high cholesterol, and an eye condition called age-related macular degeneration (AMD).

Astaxanthin resembles the carotene of carrots and is toted as the next wonder antioxidant. Astaxanthin also gives salmon flesh its unique color. It is abundant is krill, which are small crustaceans and are found in all the world’s oceans.

Wild Pacific salmon, especially sockeye salmon, have high astaxanthin content. However one has to eat about 6 ounces (165 grams) daily to get a 3.6 milligram dose.

Over the last few years krill oil has been marketed as the ultimate source of astaxanthin but laboratory results show BlueOcean’s shrimp oil contains ten times more astaxanthin that the leading krill oil brand.

This puts BlueOcean in position to tap three huge markets.

Heart health supplements are a $4B market and are dominated by omega-3 products.  Krill and shrimp oil alone are expected to make up a $2. 3B market by 2020. 

Sport supplements are a $10B global market. Muscle endurance and post-exercise recovery are the key benefits sought by consumers.

Joint and bone health supplements make up a $9B market, which targets inflammation as the primary source of joint pain.

The rising cost of healthcare expenditures by consumers around the world is expected to continue to drive usage of nutraceutical. Moreover, some nutraceuticals are regarded as alternatives to over the counter and prescription drugs

BlueOcean has entered the market with a line of sustainable omega-3/astaxanthin shrimp oil products, which are muscling innovation in the rapidly growing Omega-3 oil market where krill oil has been king as a source of astaxanthin.

The Company’s products are available for sale on five online sites (Amazon.com, Luckyvitamin.com, VitaminWorld.com and Inboxfitness.com) and in 30 Vitamin World stores in the US to date with more online and in-store retail sales channels being aggressively pursued along with further bulk Omega-3 shrimp oil sales.


Dr. Luc Duchesne

Editor:

Dr. Luc C. Duchesne is a Speaker and Author with a PhD in Biochemistry. With three decades of scientific and business experience, he has published ... <Read more about Dr. Luc Duchesne>


Copyright © 2017 InvestorIntel Corp. All rights reserved. More & Disclaimer »


Leave a Reply

Your email address will not be published. Required fields are marked *